P-0228 - Ocular toxicities with oxaliplatin in colorectal cancer
|Date||28 June 2014|
|Event||World GI 2014|
|Topics|| Complications of Treatment
|Presenter||Esther Una Cidon|
|Citation||Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165|
E. Una Cidon1, P. Alonso2
Oxaliplatin is a third generation platinum derivative, used mainly for gastrointestinal tumors. Ocular toxicity is uncommon but it has been reported. In fact, it may produce a variety of ocular changes, most of them being transient and reversible.
We carried out a retrospective study to evaluate ocular toxicities in patients who received oxaliplatin for colorectal cancer.
365 patients were evaluated and ocular toxicities were documented in 38. 61% had metastatic colorectal cancer. In 96% oxaliplatin was combined with a fluoropyrimidine. The most frequent ocular toxicities seen were tearing (52%), dry eyes (29%), conjunctivitis (15%), blurred vision (34%), vision of bright lights especially at night (14%), altered colour vision (9%), visual loss (58%) and eye pain (12%). None of these patients had a permanent damage. After stopping the chemotherapy all of the toxicities were recovered. The fluoropyrimidines may have played a role in these toxicities too though it is difficult to know exactly which.
Unfortunately, the mechanism of this toxicity remains unknown, therefore further studies are expected to bring clarity.